However, PD-1/PD-L1 blockade immunotherapy failed to show any significant clinical benefit in microsatellite-stable (MSS)/MMR-proficient (pMMR) metastatic colorectal cancer [3,4]. This evidence concerns the gene PDCD1 and metastatic colorectal cancer.